A Phase I Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancer

Protocol
11-170
Full Title
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Patients with Advanced Solid Malignancies
Phase
I
Purpose

Fibroblast growth factor receptor 1 (FGFR1) is a protein that is overproduced in some squamous cell lung cancers, leading to uncontrolled cell growth and multiplication. AZD4547 is an investigational drug that may cause tumor shrinkage by blocking the FGFR1 protein.

The purpose of this study is to evaluate the safety of AZD4547 in patients with squamous cell lung cancers whose tumors overproduce FGFR1. AZD4547 is pill that is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have squamous cell lung cancer that continues to grow despite therapy and which overproduces FGFR1.
  • Patients must have recovered from the serious side effects of prior therapies.
  • Patients must be age 25 or older.

For more information about this study or to inquire about eligibility, please contact Dr. Paul K. Paik at 646-888-4202.

Disease(s)
Lung Cancer, Non-Small Cell
Locations
Related Diseases